ADVERTISEMENT
Middle East and Africa
Hikma has picked up the commercialization rights to half-a-dozen Celltrion biosimilars in the Middle East and North Africa, in the latest agreement between the pair.
Chinese developer and manufacturer Bio-Thera Solutions has struck a further licensing agreement for one of its biosimilar candidates, this time for a proposed rival to Cosentyx (secukinumab).
MS Pharma is building on its strategic shift to expand its biosimilar business by gaining commercialization rights to Polpharma’s vedolizumab, ocrelizumab, and guselkumab candidates.
MENA specialist MS Pharma has been building up a portfolio of licensed biosimilars in recent years to build on its generics roots, seeking a first-mover advantage in key markets as well as benefiting from local manufacturing operations. Chief executive Kalle Känd sets out the firm’s strategy.
Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
Formycon and MS Pharma have followed up on previous biosimilar collaborations in the MENA region with a fresh alliance on Stelara rival FYB202.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Lupin has added two ADHD drugs to its Canadian portfolio, while also signing multiple branded deals in other global markets.
Europe Must Turn To Science Diplomacy With Developing Countries To Counter Tomorrow’s Health Threats
Public-private partnerships can help industry better understand neglected diseases and develop potential treatments.
Neuraxpharm is making further waves outside of Europe, launching operations in the Middle East just a year after entering Central and South America.
The results from a trio of studies show that AI-powered digital stethoscopes are effective at identifying patients at elevated risk of experiencing heart attacks and other major cardiac adverse events, according to Eko Health, whose technology was used to screen the participants in the studies.